This episode of ByteSight features Dr. Christian Tidona, CEO of BioMed X, a pioneering pharma innovation hub that has deployed over €100M in investment, partnered with 14+ pharma companies, and supported 30+ R&D teams since 2013. Trained as a molecular biologist at the University of Heidelberg, Christian built his career at the fault line between academic research and industrial drug development, which is a gap he has spent over a decade redesigning from the ground up.
In this conversation, Manasi and Christian explore why brilliant science so rarely reaches patients: from the „hammer looking for a nail” problem in biotech startups, to clinical trials built almost exclusively around white, middle-aged men, to the promise and limits of AI in accelerating drug discovery. They also discuss BioMed X’s recent Barbados project, a government partnership using AI and deep phenotyping to address diabetic kidney disease in a population of African descent that mainstream research has long ignored.
About Dr. Christian Tidona
Christian Tidona is a scientist entrepreneur and CEO of BioMed X, a leading innovation hub for pharma. He studied biology and received his doctoral degree in natural sciences from the University of Heidelberg. Throughout his career, his focus was always on seeding innovation at the interface between academia and industry. Christian is co-founder of BioRN in Heidelberg, the cluster management organization at the heart of one of the strongest biomedical innovation hubs in Europe, co-founder of the Heidelberg Institute for Stem Cell Technology and Experimental Medicine HI-STEM, and member of the Board of Directors of Yeda Research and Development, one of the world’s most renowned technology transfer organizations at the Weizmann Institute of Science in Israel. Christian is married and father of two children.
The “Hammer Looking for a Nail”: Why Biotech Startups Fail
Christian’s insight into the translational gap didn’t come from theory. Rather, it came from failure. After his first startup collapsed, he set out to understand why so many biotech companies with genuinely good science never make it. His diagnosis was sharp: most academic spinouts build a solution and then go looking for a problem large enough to justify it. Without an industry partner aligned from day one, funding dries up and the technology dies regardless of its merit.
As Christian puts it:
You build something that is a solution, and now you’re looking for a problem that’s big enough solving. And if you don’t find that problem, funding will dry out, and despite the fact that it’s great technology, the company will die.
BioMed X was built to solve this directly. Its model co-creates research teams from day one, half scientists from pharma, half from academia, so that what emerges is both scientifically novel and industry-grade by design.
The Representation Gap: Who Is Medicine Actually Built For?
The conversation turns to a harder problem: the evidence base underpinning modern medicine was built on a narrow slice of humanity. Clinical trials have historically enrolled white, middle-aged men as the default. Young people, women, the elderly, and patients from non-Caucasian backgrounds are systematically underrepresented, meaning that a drug validated in one population may simply not work, or may actively harm, another.
Most clinical trials, because it has always been done that way, are done with white, middle-aged subjects. These clinical trials are completely neglecting that young and old people, females, people with other ethnic backgrounds might function fundamentally differently, and that a drug that works in a white, middle-aged man might not work in a woman in the Caribbean, that is of African descent.
Christian doesn’t frame this as a problem alone. He sees the advent of AI as a genuine opportunity to close what he calls the „low-density areas” in our medical models. With the right fine-tuning, AI could potentially use a large existing dataset of white male patients to predict what a much smaller dataset from an underrepresented group would reveal, dramatically reducing the cost and scale of inclusive research.
BioMed X’s Barbados project is a direct test of whether this vision is achievable. This project combines deep epidemiological phenotyping with AI modelling to understand the genetic, behavioural, and environmental drivers of diabetic kidney disease in a population of approximately 260,000 people, predominantly of West African descent, where roughly 20% are diabetic and many progress to dialysis. The ambition goes beyond the island: Barbados is the proof of concept, designed to be replicated across Latin America, Asia, and the Global South wherever populations have been left out of the datasets medicine is built on.
If you can make this work in such a confined environment for such a specific population, you can make it work everywhere.
AI in Drug Discovery: Real Promise, Real Limits
On the question of AI’s transformative potential in pharma, Christian offers a characteristically grounded view. Yes, AI is fundamentally changing how researchers work. Yes, large language models, vibe coding, and generative tools are already reshaping scientific workflows. But the regulatory system will remain a long-term constraint.
More critically, many AI models in drug discovery remain black boxes: systems that produce confident predictions without being able to explain them. In a field where wrong answers can be fatal, that is not acceptable.
We need to fundamentally move into explainable models. And we need to find new collaboration models, because most of these biotechs don’t get access to the actual data inside the walls of pharmaceutical companies, clinical trial data and so on. It’s a sacred silo.
Final Takeaway
Talent, Christian argues, is distributed evenly across the globe. Opportunity is not. And that asymmetry is at the root of medicine’s translational gap: the patients who most need new therapies are the least likely to be included in the research that produces them.
Closing the gap requires more than better algorithms. It requires new models of collaboration between academia and industry, new approaches to clinical trial design, new willingness to share data across institutional walls, and a long-term commitment to recruiting and developing scientific talent from every corner of the world.
